SCHEMBL24196742

SCHEMBL24196742

Cc1csc2ncnc(NCCC3=CCCCCC3)c12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.55
HTT P42858 5/20 0.55
RAB9A P51151 4/20 0.55
ALDH1A1 P00352 6/20 0.50
TP53 P04637 4/20 0.50
LMNA P02545 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
MAPT P10636 6/20 0.47
KDM4E B2RXH2 3/20 0.45
GALR3 O60755 1/20 0.45
GAA P10253 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
HPGD P15428 2/20 0.44
NPC1 O15118 1/20 0.44
ALOX15 P16050 1/20 0.43
MAPK1 P28482 2/20 0.43
POLB P06746 1/20 0.43
IRAK4 Q9NWZ3 1/20 0.41
CSNK2A2 P19784 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26255155 0.99 SMN1; SMN2 (0.56) SMN1; SMN2HTTRAB9AALDH1A1TP53
SCHEMBL2369554 0.79 ALDH1A1 (0.57) SMN1; SMN2HTTRAB9AALDH1A1TP53
SCHEMBL14623890 0.78 CSNK2A2 (0.65) SMN1; SMN2HTTALDH1A1TP53LMNA
SCHEMBL24196758 0.78 ALDH1A1 (0.53) SMN1; SMN2HTTRAB9AALDH1A1TP53
SCHEMBL24197035 0.77 RAB9A (0.53) SMN1; SMN2HTTRAB9AALDH1A1TP53
SCHEMBL24196741 0.77 HTT (0.54) SMN1; SMN2HTTRAB9AALDH1A1TP53
SCHEMBL26255174 0.76 ALDH1A1 (0.54) SMN1; SMN2HTTRAB9AALDH1A1TP53
SCHEMBL26255166 0.76 RAB9A (0.54) SMN1; SMN2HTTRAB9AALDH1A1TP53
SCHEMBL13431476 0.76 SMN1; SMN2 (0.65) SMN1; SMN2HTTRAB9AALDH1A1TP53
SCHEMBL3342400 0.75 SMN1; SMN2 (0.62) SMN1; SMN2HTTRAB9AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279006-A1 NOVEL COMPOUNDS AND METHODS FOR INCREASING KLOTHO GENE EXPRESSION KLOTHO THERAPEUTICS, INC. 2023-09-07 US disclosed
US-20230279006-A1 NOVEL COMPOUNDS AND METHODS FOR INCREASING KLOTHO GENE EXPRESSION KLOTHO THERAPEUTICS, INC. 2023-09-07 US disclosed
WO-2022011171-A1 NOVEL COMPOUNDS AND METHODS FOR INCREASING KLOTHO GENE EXPRESSION KLOTHO THERAPEUTICS, INC. (US) 2022-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279006-A1 NOVEL COMPOUNDS AND METHODS FOR INCREASING KLOTHO GENE EXPRESSION KLKB1, KLK2, KLK1 SMN1; SMN2 4641/4885HTT 2317/4885RAB9A 3861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.